Table 1. Clinical characteristics of the patients with aortic valve stenosis.
| Subject | Sex | Age. y | BMI | Diagnosis | Clinical history | Statin | Smoking | Dys-lipidemia | Valve leaflet weight (mg) |
| A | F | 67 | 29 | AS | Diabetes | + | − | + | 1892 |
| B | F | 82 | 22 | AS+AI | Hypertension, diabetes | − | − | + | 633 |
| C | M | 73 | 23 | AS | Diabetes | + | + | + | 605 |
| D | F | 70 | 26 | AS | - | − | − | − | 1773 |
| E | M | 81 | 24 | AS | Hypertension, kidney disease | − | − | − | 2067 |
| F | M | 74 | N/A | AS | Hypertension | + | − | + | 930 |
| G | M | 58 | 28 | AS | Hypertension, diabetes, TIA/stroke | + | + | + | 1876 |
| H | F | 75 | 30 | AS | - | − | − | + | 1476 |
| I | M | 80 | 22 | AS | Hypertension | + | + | + | 1393 |
| J | F | 61 | 23 | AS | - | − | + | − | 1520 |
| K | F | 70 | 31 | AS | TIA/stroke | + | − | + | 659 and 767 |
| L | M | 53 | 22 | AS | - | + | + | + | 1950 and 1080 |
| M | M | 53 | 27 | AS | Hypertension | + | − | + | 1827 and 2367 |
| N | M | 64 | 37 | AS | Diabetes | − | − | + | 1668 |
| O | F | 86 | N/A | AS | - | − | − | N/A | 852 |
| P | F | 72 | 21 | AS | Hypertension | + | − | + | 779 |
| Q | M | 43 | 37 | AS | - | + | − | + | 4367 |
| R | M | 37 | 27 | AS+AI | Hypertension | − | + | + | 295 |
| S | F | 86 | 22 | AS+AI | - | − | − | − | 2308 |
| T | F | 75 | 30 | AS | - | − | − | − | 392 |
| U | F | 65 | 28 | AS+AI | - | − | − | N/A | 778 |
| V | F | 76 | 33 | AS | Hypertension, Diabetes | + | − | + | 1321 |
| X | M | 63 | 31 | AS | Hypertension | + | + | + | 1594 |
AS indicates aortic stenosis; AI, aortic insufficiency; N/A, data not available. Aortic valve leaflets of patients A–O were used for characterization of the size and composition of the extracellular particles. Extracellular particles isolated from the valve leaflets of patients P and Q, and from additional leaflets of patients K, L and M were assayed for oxidative modification. Valve leaflets of patients R–X were used for lipid extraction and lipidomic analysis by mass spectrometry.